Table 1. Characteristics of Patients with (Group 1) and without (Group 2) Neoadjuvant Denosumab.
| Characteristic | All patients (n =123) | Group 1 (n = 42) | Group 2 (n = 81) | p-value |
|---|---|---|---|---|
| Age (yr) | 29.6 ± 9.8 | 27.4 ± 11.6 | 30.6 ± 10.4 | 0.456 |
| Sex | 0.961 | |||
| Male | 87 (70.7) | 29 (69.0) | 58 (71.6) | |
| Female | 36 (29.3) | 13 (31.0) | 23 (28.4) | |
| Duration of symptom (mo) | 4.6 ± 3.1 | 4.8 ± 3.8 | 4.3 ± 2.8 | 0.425 |
| History of trauma | 28 (22.7) | 9 (21.4) | 19 (23.4) | 0.564 |
| Site | 0.063 | |||
| Distal femur | 30 (24.4) | 11 (26.2) | 19 (23.4) | |
| Proximal tibia | 24 (19.5) | 10 (23.8) | 14 (17.2) | |
| Distal radius | 14 (11.3) | 4 (9.5) | 10 (12.3) | |
| Pelvis | 12 (9.7) | 6 (14.2) | 6 (7.4) | |
| Foot | 10 (8.1) | 4 (9.5) | 6 (7.4) | |
| Distal tibia | 8 (6.5) | 1 (2.3) | 7 (8.6) | |
| Hand | 8 (6.5) | 3 (7.1) | 5 (6.1) | |
| Distal humerus | 5 (4.0) | 1 (2.3) | 4 (4.9) | |
| Proximal humerus | 5 (4.0) | 0 | 5 (6.1) | |
| Proximal femur | 3 (2.4) | 1 (2.3) | 2 (2.4) | |
| Proximal fibula | 2 (1.6) | 0 | 2 (2.4) | |
| Distal ulna | 2 (1.6) | 1 (2.3) | 1 (1.2) | |
| Size of lesion (cm3) | 3.7 ± 2.4 | 4.1 ± 2.6 | 3.5 ± 3.7 | 0.087 |
| Pathological fracture | 11 (8.9) | 4 (9.5) | 7 (8.6) | 0.233 |
| Pulmonary metastasis | 8 (6.5) | 3 (7.1) | 5 (6.1) | 0.365 |
| Campanacci grade (plain radiograph) | 0.036* | |||
| Grade 1 | 9 (5.2) | 0 | 9 (8.6) | |
| Grade 2 | 81 (52.0) | 25 (40.6) | 56 (59.6) | |
| Grade 3 | 33 (42.8) | 17 (59.4) | 16 (31.7) | |
| Serum alkaline phosphatase (IU/L) | 87.3 ± 35.4 | 98.3 ± 21.5 | 82.3 ± 30.4 | 0.096 |
| Serum calcium (mg/dL) | 9.1 ± 1.7 | 8.7 ± 2.1 | 9.3 ± 1.7 | 0.894 |
| Duration of surgery (min) | 103 ± 42 | 124 ± 36 | 89 ± 65 | 0.149 |
| Intraoperative blood loss (mL) | 142 ± 61 | 123 ± 59 | 156 ± 47 | 0.067 |
| Postoperative complication | 7 (5.6) | 2 (4.7) | 5 (6.1) | 0.119 |
| Follow-up | ||||
| Local recurrence | 33 (26.8) | 18 (42.8) | 15 (18.5) | < 0.001* |
| MSTS score at 3 months | 16.4 ± 3.1 | 17.0 ± 3.6 | 16.1 ± 3.9 | 0.621 |
| MSTS score at 6 months | 24.2 ± 3.1 | 25.1 ± 2.8 | 23.8 ± 3.6 | 0.224 |
| MSTS score at 1 year | 28.5 ± 1.5 | 29.0 ± 1.2 | 28.1 ± 2.1 | 0.724 |
| Duration of follow-up (mo) | 35 ± 20 | 32 ± 22 | 37 ± 19 | 0.533 |
Values are presented as mean ± standard deviation or number (%).
MSTS: Musculoskeletal Tumor Society.
*Indicates statistical significance.